ROCHESTER, N.Y., March 10, 2017 /PRNewswire/ -- Koning Corporation announced that Koning Breast CT has received an Innovative Technology contract from Vizient, Inc. the largest member-driven health care performance improvement company in the country. The contract was based on a recommendation of Koning Breast CT by hospital representatives with expertise in this category who serve on one of Vizient's member-led councils. Vizient reserves Innovative Technology contracts for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization's care delivery and business model.
Koning's Breast CT (KBCT) device is the only FDA-approved breast CT imaging system on the market. A unique modality, the KBCT provides real 3D isotropic multi-planar images of the breast - without compression and with high dose efficiency. This technology allows for precise detection, assessment, and quantification of abnormalities, especially in women with dense breast tissue. The KBCT represents a step function change in breast cancer diagnosis, both in patient comfort, clinical results, and hospital capital efficiency.
At Koning our vision is to create a revolution in medical imaging through our advanced Computed Tomography technology. We believe our Koning Breast CT will dramatically improve the way clinicians visualize and evaluate breast tissue. Future versions of our technology are expected to optimize early disease detection, diagnosis, intervention and treatment. Our hope is to be able to improve survival rates and outcomes for millions of patients. We believe that the power, versatility, and lower cost of Koning Breast CT will serve as a viable substitute for many traditional breast imaging applications. We are truly excited to be part of the Vizient portfolio and bring this game changing technology with contract pricing to Vizient members everywhere.
"Products and services are often released and marketed as innovative. Our member hospitals truly value the thorough review process in place at Vizient to help them identify innovative technology products worth further evaluation at their own facilities," said Debbie Archer, director of procurement and leader of Vizient's Innovative Technology program for suppliers. "After a full review of Koning Breast CT, Vizient's member council for this product category agreed it offers unique and incremental benefit over other available products, and recommended it for an Innovative Technology contract. We are pleased to award this new contract to Koning Corporation."
Vizient, Inc. represents the combined strengths of the organizations formerly known as VHA Inc., University HealthSystem Consortium, Novation and MedAssets' Spend and Clinical Resource Management. Since 2003, nearly 2200 new and innovative products and technologies have been submitted through the Vizient Innovative Technology program. Vizient works with member-led councils and task forces to identify and review potentially innovative products. If it is determined that a product is innovative, a contract may be awarded outside of Vizient's competitive bid cycle.
Globally, breast cancer is an ever-growing problem and the well documented limitations of current methods for diagnosis have been significantly challenged, especially in dense breast tissue. Developing a non-compressional breast imaging device that provides a real 3D imaging capability at low radiation doses was the primary focus in the development of the Koning dedicated breast CT. Advanced CT imaging has been the gold standard for head, neck, chest, and abdomen imaging for decades. Now, those same advanced imaging benefits and diagnostic capabilities have been brought to breast with the KBCT.
Koning Corporation's KBCT was FDA-approved in January 2015, making it the first dedicated breast CT imaging system to launch in the North American marketplace. A unique modality, the KBCT provides 3D isotropic multi-planar images of the breast - without compression and with high dose efficiency within the 10-second scan. Another major performance advantage of the KBCT technology is the ability to perform 3D image-guided biopsies as part of the diagnostic scanning workflow when needed. Combining multiple applications into one device provides economic benefit when compared to the add on or standalone biopsy devices commonly in use. KBCT 3D guided biopsy can cut the dose by half compared to add-on or prone stereotactic biopsy systems.
SOURCE Koning Corporation